News

BioMotiv, a mission-driven drug development accelerator that advances breakthrough discoveries from research institutions into therapeutics, and Bristol-Myers Squibb Company announced a…
Read More...

Celltrion and Lonza announced a contract manufacturing agreement to produce drug substance for Remsima, a biosimilar approved by the EMA and the FDA for a number of autoimmune diseases…
Read More...

Allergan plc announced it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE cannula…
Read More...

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system…
Read More...

Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into a global commercialization agreement for a proposed natalizumab biosimilar. The…
Read More...

Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, announces it has closed a £100 million Series B financing led by incoming U.S.…
Read More...

Cidara Therapeutics, Inc. and Mundipharma announced that they have entered into a strategic partnership to develop and commercialize rezafungin for the treatment and prevention of…
Read More...

Vertex Pharmaceuticals Incorporated announced that the company has entered into a definitive agreement under which Vertex will acquire Semma Therapeutics, a privately held biotechnology…
Read More...

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, together with Blanver Farmoquímica e Farmacêutica S.A., a Brazilian company focused on innovative…
Read More...

Valo Therapeutics Limited (Valo Tx), an immuno-oncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines, announced that it has licensed proprietary…
Read More...

Roche announced that the phase III MINISTONE-2 study showed that one-dose Xofluza (baloxavir marboxil) was a well-tolerated and effective potential treatment for flu in otherwise…
Read More...

Novartis announced results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of Entresto (sacubitril/valsartan) in patients with…
Read More...

BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, announced completion of construction of a new state-of-the-art manufacturing facility. The new…
Read More...

LabCorp announced that its Covance Drug Development business has launched a laboratory solution within its functional service provider (FSPx) offering. Covance has been offering FSP…
Read More...

Novartis announced full results from its global Phase III PARAGON-HF study, investigating the efficacy and safety of Entresto (sacubitril/valsartan) versus the active comparator…
Read More...

Ajinomoto Bio-Pharma Services announced its intention to purchase the remaining 50 percent ownership interest in its Visakhapatnam, India joint venture, Granules OmniChem Private…
Read More...

Roche announced that the European Commission has approved Tecentriq (atezolizumab) plus chemotherapy (Abraxane ) for the treatment of adult patients with unresectable locally advanced…
Read More...

AstraZeneca announced that the Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary endpoint,…
Read More...

AbbVie announced that MERU, a Phase 3 trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit at a…
Read More...

Esperion announced positive top-line results from the Phase 2 bempedoic acid / ezetimibe combination tablet study (1002-058). This was a randomized, double-blind, parallel group study…
Read More...